Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Intellia Therapeutics
Biotech
Intellia opts out of hemophilia gene editing work with Regeneron
Intellia is opting out of a hemophilia program, leaving the CRISPR/Cas9 gene editing work on factor IX treatments in the hands of partner Regeneron.
Annalee Armstrong
Mar 22, 2024 11:21am
KalVista's persistence with sebetralstat pays off in ph. 3 win
Feb 13, 2024 6:30am
JPM24, Day 3: Gene editors talk BD; Roivant has cash to spend
Jan 10, 2024 4:38pm
Intellia, Aera the latest gene editing biotechs to lay off staff
Jan 4, 2024 6:50pm
Trio of biotechs toss programs to discard pile
Nov 9, 2023 11:23am
Intellia preps first ph. 3 trial of in vivo CRISPR therapy in US
Oct 18, 2023 10:15am